Survodutide Improves Liver Disease Progression in More than

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

Related Keywords

United States , Carinne Brouillon , Tarun Sanyal , Boehringer Ingelheim , Molecular Pathology , Virginia Commonwealth University School , Non Alcoholic Fatty Liver Disease Activity Score , Track Designation , Priority Medicine , Human Pharma ,